Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Neoplasms, Vascular Tissue

Petit, A.M. et al., Erber, R. et al., Abounader, R. et al., Zeng, Q. et al., Carnemolla, B. et al., et al.

Koskinen, Bono, Leivo, Vaheri, Aaltonen, Joensuu,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Neoplasms, Vascular Tissue

SF/HGF and c-Met are expressed in brain tumors, the expression levels frequently correlating with tumor grade, tumor blood vessel density, and poor prognosis [1].

High impact information on Neoplasms, Vascular Tissue

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix [2].
Prominent suppression of VEGF/VPF expression in vivo, as well as a significant reduction in tumor blood vessel counts, were also observed in established A431 tumors shortly after injection of the antibody as few as four times into nude mice [3].
Tumor blood vessel density (BVD) was assessed using immunostaining for CD31 [4].
Moreover, the level of Jagged1 was significantly correlated with tumor blood vessel content and associated with HNSCC development [5].
TUNEL staining, electron microscopy, and apoptosis blocking experiments suggest that VEGFR-2 plus PDGFR-beta targeting enforced tumor blood vessel regression by inducing endothelial cell apoptosis [6].

References

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Abounader, R., Laterra, J. Neuro-oncology (2005) [Pubmed]
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., Zardi, L. Blood (2002) [Pubmed]
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B., Kerbel, R.S. Am. J. Pathol. (1997) [Pubmed]
Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression. Koskinen, W.J., Bono, P., Leivo, I., Vaheri, A., Aaltonen, L.M., Joensuu, H. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (2005) [Pubmed]
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Zeng, Q., Li, S., Chepeha, D.B., Giordano, T.J., Li, J., Zhang, H., Polverini, P.J., Nor, J., Kitajewski, J., Wang, C.Y. Cancer Cell (2005) [Pubmed]
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Erber, R., Thurnher, A., Katsen, A.D., Groth, G., Kerger, H., Hammes, H.P., Menger, M.D., Ullrich, A., Vajkoczy, P. FASEB J. (2004) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share